Open AccessSingle‐cell profiling guided combination therapy of c‐Fos and histone deacetylase inhibitors in diffuse large B‐cell lymphoma
Author(s) -
Krämer Oliver H.,
Schneider Günter
Publication year - 2022
Publication title -
clinical and translational medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.125
H-Index - 1
ISSN - 2001-1326
DOI - 10.1002/ctm2.858
Subject(s) - histone deacetylase , epigenetics , histone deacetylase inhibitor , cancer research , histone , diffuse large b cell lymphoma , medicine , computational biology , transcription factor , vorinostat , lymphoma , bioinformatics , biology , genetics , gene
In this commentary on Wang, Wu, Xia, and colleagues, Clinical Translational Medicine , 2022, we sum up and discuss recent evidence on the regulation and relevance of the transcription factor c‐FOS in diffuse large B cell lymphoma cells that are treated with epigenetic erasers of the histone deacetylase inhibitor family.